![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department of Clinical Pharmaceutical Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Tsushima-naka, Okayama, Japan (Y.H., N.H., J.H., S.A., F.T., H.K.); Department of Hospital Pharmacy, Okayama University Hospital of Medicine and Dentistry, Shikata-cho, Okayama, Japan (H.N., Y.G.); and Centre for Integrated Research in Science, Shimane University, Enya-cho, Izumo, Japan (Y.K.)
Received August 24, 2005; accepted October 17, 2005.
| Abstract |
|---|
|
|
|---|
-nitro-L-arginine methyl ester (L-NAME) and N-
-nitro-L-arginine (L-NNA)] and specific neuronal NOS (nNOS) inhibitor [vinyl-L-N-5-(1-imino-3-butenyl)-L-ornithine (L-VNIO)] on adrenergic nerve-mediated vasoconstriction were studied in rat perfused mesenteric vascular beds without endothelium. Perfusion of L-NAME, L-NNA, or L-VNIO markedly augmented vasoconstrictor responses to periarterial nerve stimulation (PNS; 2-8 Hz) without affecting vasoconstriction induced by exogenously injected norepinephrine (NE). Addition of L-arginine, a precursor for the synthesis of nitric oxide (NO), reversed the augmentation of the PNS response by L-NAME. The PNS (8 Hz)-evoked NE release in the perfusate was increased by L-NAME perfusion. In preparations treated with capsaicin [a depleter of calcitonin gene-related peptide (CGRP)-containing nerves], L-NAME did not augment vasoconstrictor responses to PNS or NE injection. Combined perfusion of CGRP(8-37) (a CGRP receptor antagonist) and L-NAME induced additive augmentation of the vasoconstrictor response to PNS but did not affect the response to NE injection. In preparations with active tone produced by methoxamine and in the presence of guanethidine, L-NAME perfusion did not affect the vasodilator response induced by PNS. Immunostaining of the mesenteric artery showed the presence of nNOS-like immunopositive nerve fibers, which were absent in arteries pretreated with capsaicin. These findings suggest that NO, which is released from perivascular capsaicin-sensitive nerves, presynaptically inhibits neurogenic NE release to modulate adrenergic neurotransmission.
Nitric oxide (NO) is synthesized from L-arginine by NO synthase (NOS) in various cells. NOS is present not only in vascular endothelial cells (endothelial NOS) but also in perivascular nerves [neuronal NOS (nNOS)] (Moncada and Higgs, 1995
; Sosunov et al., 1995
). Inhibition of NOS by NOS inhibitors such as the nonselective NOS inhibitor N-
-nitro-L-arginine methyl ester (L-NAME) has been reported to augment the vasoconstrictor effect induced by PNS in various isolated blood vessels, whereas the enhanced PNS-induced responses to NOS inhibitors are reversed by L-arginine, a precursor for the synthesis of NO, and involve the endothelium-derived NO (Toda and Okamura, 1990
; Postorino et al., 1998
). On the other hand, several studies showed that NOS inhibitors have no effect on vasoconstriction in response to PNS in dog pulmonary arteries and human omental arteries without endothelium (Aldasoro et al., 1993
; Segarra et al., 1999
). In rat mesenteric arteries with endothelium, some reports have described that NOS inhibitors enhanced the vasoconstrictor responses to PNS (Yamamoto et al., 1997
; Boric et al., 1999
), suggesting the involvement of endothelial NO. However, it remains unclear whether perivascular NOS-containing nerves modulate adrenergic neurotransmission.
The aim of this study was to clarify the mechanism underlying the augmentation of adrenergic nerve-mediated vasoconstriction induced by nonselective NOS inhibitors, L-NAME and N-
-nitro-L-arginine (L-NNA), and a selective nNOS inhibitor, vinyl-L-N-5-(1-imino-3-butenyl)-L-ornithine (L-VNIO), in rat perfused mesenteric vascular beds. Additionally, the present study was designed to investigate the possible involvement of perivascular NANC nerves in the effects of NOS inhibitors. To avoid the potential confounding effects of endothelium-dependent NO release, the present study was performed in mesenteric arteries de-endothelialized with sodium deoxycholate (SD).
| Materials and Methods |
|---|
|
|
|---|
The isolated mesenteric vascular bed was perfused with Krebs' solution at a constant flow rate of 5 ml/min with a peristaltic pump (model AC-2120; Atto Bioscience, Rockville, MD) and superfused with the same solution at a rate of 0.5 ml/min to prevent drying. The Krebs' solution was bubbled with a mixture of 95% O2 and 5% CO2. The modified Krebs' solution had the following composition: 119.0 mM NaCl, 4.7 mM KCl, 2.4 mM CaCl2, 1.2 mM MgSO4, 25.0 mM NaHCO3, 1.2 mM KH2PO4, 0.03 mM EDTA-2Na, and 11.1 mM glucose, pH 7.4. Changes in the perfusion pressure were measured with a pressure transducer (model TP-400T; Nihon Bunko, Tokyo, Japan) and recorded using a pen recorder (model U-228; Nippon Kayaku, Tokyo, Japan).
Chemical Removal of Vascular Endothelium. To remove the vascular endothelium, preparations with resting tone were perfused with 1.80 mg/ml SD in saline for 30 s as described previously (Takenaga and Kawasaki, 1999
; Shiraki et al., 2000
). The preparations were then rinsed with SD-free Krebs' solution for 1 h.
PNS and Bolus Injection of NE. PNS at 2, 4, and 8 Hz was applied at 7-min intervals using bipolar platinum ring electrodes placed around the superior mesenteric artery. Rectangular pulses of 1 ms and supramaximal voltage (50 V) were applied for 30 s using an electronic stimulator (model SEN 3301; Nihon Bunko).
NE was directly injected into the perfusate proximal to the arterial cannula with an infusion pump (model 975; Harvard Apparatus Inc., Holliston, MA). A volume of 100 µl was injected during a period of 12 s.
Experimental Protocols for Preparations with Resting Tone. After responses to the first PNS (S1) and NE injection (I1) were obtained as the controls, the Krebs' solution was switched to Krebs' solution containing L-NAME (1, 10, or 100 µM), L-NNA (1, 10, or 100 µM), L-VNIO (10 or 100 µM), CGRP(8-37) (CGRP receptor antagonist, 100 nM), L-NAME (100 µM) plus L-arginine (10 or 100 µM or 1 mM), or L-NAME (100 µM) plus CGRP(8-37) (100 nM), and then the second PNS (S2) and NE injection (I2) were carried out. Perfusion of these agents was began 20 min before and continued throughout PNS or NE injection. To estimate the effects of the agents tested, changes in perfusion pressure in response to PNS or NE injection were expressed as the ratio between the vasoconstriction induced by S2 and S1 or I2 and I1, respectively.
For capsaicin treatment, the preparation was perfused first with Krebs' solution containing 5 µM capsaicin for 20 min. After discontinuation of the capsaicin perfusion, the preparation was rinsed with capsaicin-free Krebs' solution for 30 min and subsequently perfused with sodium deoxycholate as described above.
At the end of each experiment, the preparations were perfused with Krebs' solution containing 2 µM methoxamine, a selective
1 adrenoceptor agonist, to produce vascular tone and 5 µM guanethidine to block adrenergic neurotransmission. Chemical removal of the endothelium was assessed by verifying the lack of a relaxant effect after a bolus injection of 1 nmol acetylcholine (ACh). Thereafter, to assess the denervation of NANC nerves by capsaicin, 2 Hz PNS was applied.
Experimental Protocols for Preparations with Active Tone. The effect of L-NAME on CGRPergic nerve-mediated and exogenous CGRP-induced vasodilation was examined in denuded mesenteric vascular beds with active tone. After responses to the first PNS (S1, 1 and 2 Hz) and CGRP (I1, 10 pmol) injection were obtained as the control, the Krebs' solution containing 2 µM methoxamine and 5 µM guanethidine was switched to Krebs' solution containing 2 µM methoxamine, 5 µM guanethidine, and 100 µM L-NAME, and then the second PNS (S2) and CGRP injection (I2) were carried out. To quantify the effects of the peptides tested, changes in perfusion pressure in response to PNS or CGRP injection were expressed as the ratio between the vasodilation induced by S2 and S1 or I2 and I1, respectively.
At the end of each experiment, 100 µM papaverine was perfused to produce complete relaxation. Vasodilation was expressed as the percentage of the perfusion pressure at maximum relaxation induced by papaverine.
Measurement of NE in the Perfusate. In denuded preparations with resting tone, the perfusate was collected before and after the first PNS (S1, 8 Hz) for 3 min. Thereafter, the Krebs' solution was switched to Krebs' solution containing L-NAME (100 µM), and then the perfusate was collected before and after the second PNS (S2).
NE in the perfusate was adsorbed onto the alumina, and the extract obtained with acetic acid was assayed by high-performance liquid chromatography with an electrochemical detector (model HTEC-500; Eicom, Kyoto, Japan). The internal standard was 3,4-dihydroxybenzylamine hydrobromide (Sigma-Aldrich, St. Louis, MO).
Immunohistochemical Study. The mesenteric artery was isolated, fixed and immersed as described previously (Hobara et al., 2004
). In another series of experiments, the isolated mesenteric artery was incubated with Krebs' solution containing capsaicin (500 µM) for 30 min and then rinsed with capsaicin-free Krebs' solution for 60 min. After rinsing, the mesenteric artery was fixed, and immunostaining was carried out as follows. The arteries were incubated with the primary antibody, anti-nNOS (1:500; raised in rabbit) (Zymed Laboratories, South San Francisco, CA), for 72 h at 4°C. After incubation, the site of the antigen-antibody reaction was revealed by incubation with fluorescein isothiocyanate-labeled goat anti-rabbit IgG (diluted 1:100) (MP Biomedicals, Irvine, CA) for 60 min. Immunofluorescence in the arteries was observed under a confocal laser-scanning microscope (CLSM 510; Carl Zeiss GmbH, Jena, Germany) in the Okayama University Medical School Central Research laboratory. Control immunohistochemical staining for nNOS blocking peptide was done by preadsorbing the blocking peptide for primary antibody to nNOS (rat) (5 µg/ml; Cayman Chemical, Ann Arbor, MI) and exhausting the nNOS antibody with the relevant peptides.
|
Drugs. The following drugs were used: ACh chloride (Daichi Pharmaceutical Co., Tokyo, Japan), capsaicin (Sigma-Aldrich), guanethidine sulfate (Tokyo Kasei, Tokyo, Japan), human CGRP(8-37) (Peptide Institute, Osaka, Japan), L-arginine (Sigma-Aldrich), L-NAME (Sigma-Aldrich), L-NNA (Sigma-Aldrich), L-VNIO (Alexis Corporation, Läufelfingen, Switzerland), NE hydrochloride (Daiichi-Sankyo, Tokyo, Japan), methoxamine hydrochloride (Nihon Shinyaku Co., Kyoto, Japan), papaverine hydrochloride (Sigma-Aldrich), rat CGRP (Peptide Institute), and SD (Ishizu Seiyaku, Tokyo, Japan). All drugs, except for capsaicin and SD, were dissolved in pure water and diluted with Krebs' solution. Capsaicin was dissolved in 50% ethanol and diluted with Krebs' solution (final alcohol concentration, 0.4 mg/ml). SD was dissolved in 0.9% saline. ACh and rat CGRP was diluted with Krebs' solution containing 2 µM methoxamine and 5 µM guanethidine when injected directly.
| Results |
|---|
|
|
|---|
1 adrenoceptor agonist, to increase vascular tone and guanethidine to block adrenergic neurotransmission. Chemical removal of the endothelium was confirmed by the lack of a relaxant effect after a bolus injection of 1 nmol ACh, and application of 2 Hz PNS caused a decrease in perfusion pressure due to vasodilation. We previously reported that PNS-induced vasodilation is mediated by endogenous CGRP released due to the stimulation of CGRPergic nerves (Kawasaki et al., 1988
|
Effect of L-Arginine on Vasoconstrictor Responses to PNS and NE Injection in the Presence of L-NAME. As shown in Fig. 3A, the augmentation of PNS-induced vasoconstriction induced by L-NAME was reversed by additional perfusion with L-arginine (10 µM to 1 mM) (Fig. 3B). However, L-arginine did not affect vasoconstrictor responses to NE injection (Fig. 3C).
|
|
|
In preparations treated with capsaicin, the basal release of NE was 7.30 ± 3.64 pg/ml (n = 6). The first PNS after the treatment evoked greater NE release (49.48 ± 3.45 pg/ml) than that in control preparations without capsaicin treatment. There was a significant difference (P < 0.01) between the capsaicin-treated and control preparations in the net release of NE (pre-PNS minus post-PNS). As shown in Fig. 5, perfusion of L-NAME (100 µM) did not alter the PNS-evoked NE release in preparations treated with capsaicin.
Effects of L-NAME, CGRP(8-37), or the Combination of L-NAME and CGRP(8-37) on Vasoconstrictor Responses to PNS and NE Injection. Perfusion of CGRP(8-37) significantly augmented the vasoconstrictor response to PNS without affecting the NE-induced vasoconstriction. CGRP(8-37) perfusion in the presence of L-NAME caused further, additive augmentation of the PNS-induced vasoconstriction (Table 1). However, the combination of L-NAME and CGRP(8-37) did not affect the NE-induced vasoconstriction (Table 1).
|
Effect of L-NAME on Vasodilation in Response to PNS and CGRP Injection. In perfused mesenteric vascular beds without endothelium and with active tone, PNS (1 and 2 Hz) induced a frequency-dependent decrease in perfusion pressure due to vasodilation. A bolus injection of CGRP (10 pmol) into the perfusate also caused vasodilation. Repeated PNS and CGRP injections caused reproducible vasoconstrictor responses. In the control response, the ratios of S1 and S2 at 1 and 2 Hz and I1 and 12 at 10 nmol were 1.12 ± 0.06 and 1.12 ± 0.02 and 1.13 ± 0.03, respectively (Fig. 6, B and C). As shown in Fig. 6, perfusion of L-NAME (100 µM) did not alter the PNS-induced or CGRP-induced vasodilation.
|
|
| Discussion |
|---|
|
|
|---|
1-adrenoceptor antagonist), and 6-hydroxydopamine (adrenergic neuron destroyer) (Kawasaki and Takasaki, 1984
Involvement of Neuronal NO. L-Arginine completely reversed the enhancement by an NOS inhibitor (L-NAME) of the adrenergic nerve-mediated response, whereas L-arginine did not affect the vasoconstrictor response to exogenously applied NE. These findings strongly suggest that endogenous NO modulates the neurogenic release of NE from adrenergic nerve terminals. In the guinea pig pulmonary artery, NO has been shown not to affect the PNS-induced NE release (Brassai et al., 2002
). In contrast, Barnes et al. (2001
) reported that NO, which is released from neuronal and endothelial sources, modulates the evoked catecholamine release from the canine adrenal medulla. In the present study, an NOS inhibitor, L-NAME, facilitated PNS-induced NE release, suggesting that endogenous NO presynaptically inhibits the neurogenic release of NE in rat mesenteric arteries.
|
Interaction with CGRPergic Nerves. Oroszi et al. (1999
) reported interplay between NO and CGRP in the isolated guinea pig heart. Furthermore, Gumusel et al. (2001
) reported that NO mediates NANC relaxation in the rat pulmonary artery and inhibits the release of NANC neurotransmitter(s), which mediate the residual relaxation. In the present study, L-NAME in the preconstricted mesenteric artery without endothelium did not alter the PNS-induced vasodilation, which is mediated by CGRPergic nerves. In contrast, Ralevic (2002
) reported that L-NAME has a postjunctional effect of inhibiting sensory neurogenic vasorelaxation in the absence of endothelium. However, the present findings showed that L-NAME did not attenuate the vasodilator response to exogenous CGRP, suggesting that L-NAME has no effect on CGRPergic vasodilation. Furthermore, the present results demonstrated that the presence of L-NAME together with CGRP(8-37) caused additive augmentation of the PNS-induced vasoconstrictor responses that were obtained with L-NAME or CGRP(8-37) alone. These results suggest that NO, which is released from perivascular capsaicin-sensitive nerves (probably CGRPergic nerves) is responsible for the presynaptic inhibition of adrenergic nerve neurotransmission but is not involved in the vasodilator response to PNS.
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
ABBREVIATIONS: NE, norepinephrine; NANC, nonadrenergic noncholinergic; PNS, periarterial nerve stimulation; CGRP, calcitonin gene-related peptide; NO, nitric oxide; NOS, nitric-oxide synthase; nNOS, neuronal NOS; L-NAME, N-
-nitro-L-arginine methyl ester; L-NNA, N-
-nitro-L-arginine; L-VNIO, vinyl-L-N-5-(1-imino-3-butenyl)-L-ornithine; SD, sodium deoxycholate; ACh, acetylcholine; LI, like immunoreactivity.
Address correspondence to: Dr. Hiromu Kawasaki, Department of Clinical Pharmaceutical Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Okayama 700-8530, Japan. E-mail: kawasaki{at}pheasant.pharm.okayama-u.ac.jp
| References |
|---|
|
|
|---|
Aldasoro M, Martinez C, Vila JM, Flor B, and Lluch S (1993) Endothelium-dependent component in the contractile responses of human omental arteries to adrenergic stimulation. Eur J Pharmacol 250: 103-107.[CrossRef][Medline]
Babu BR and Griffith OW (1998) N5-(1-Imino-3-butenyl)-L-ornithine: a neuronal isoform selective mechanism-based inactivator of nitric oxide synthase. J Biol Chem 273: 8882-8889.
Barnes RD, Ward LE, Frank KP, Tyce GM, Hunter LW, and Rorie DK (2001) Nitric oxide modulates evoked catecholamine release from canine adrenal medulla. Neuroscience 104: 1165-1173.[CrossRef][Medline]
Bevan JA and Brayden JE (1987) Nonadrenergic neural vasodilator mechanisms. Circ Res 60: 309-326.
Boric MP, Figueroa XF, Donoso MV, Paredes A, Poblete I, and Huidobro-Toro JP (1999) Rise in endothelium-derived NO after stimulation of rat perivascular sympathetic mesenteric nerves. Am J Physiol 277: H1027-H1035.[Medline]
Brassai A, Mako K, Domjanschitz L, and Sperlagh B (2002) Lack of prejunctional modulation of noradrenaline release by endogenous nitric oxide in guinea pig pulmonary artery. Neurochem Int 41: 279-283.[CrossRef][Medline]
Fujimori A, Saito A, Kimura S, Watanabe T, Uchiyama Y, Kawasaki H, and Goto K (1989) Neurogenic vasodilation and release of calcitonin gene-related peptide (CGRP) from perivascular nerves in the rat mesenteric artery. Biochem Biophys Res Commun 165: 1391-1398.[CrossRef][Medline]
Gumusel B, Orhan D, Tolunay O, and Uma S (2001) The role of nitric oxide in mediating nonadrenergic, noncholinergic relaxation in rat pulmonary artery. Nitric Oxide 5: 296-301.[CrossRef][Medline]
Hobara N, Nakamura A, Ohtsuka A, Narasaki M, Shibata K, Gomoita Y, and Kawasaki H (2004) Distribution of adrenomedullin-containing perivascular nerves in the rat mesenteric artery. Peptides 25: 589-599.[CrossRef][Medline]
Kawasaki H, Nuki C, Saito A, and Takasaki K (1990) Role of calcitonin gene-related peptide-containing nerves in the vascular adrenergic neurotransmission. J Pharmacol Exp Ther 252: 403-409.
Kawasaki H, Nuki C, Saito A, and Takasaki K (1991) NPY modulates neurotransmission of CGRP-containing vasodilator nerves in rat mesenteric arteries. Am J Physiol 261: H683-H690.[Medline]
Kawasaki H and Takasaki K (1984) Vasoconstrictor response induced by 5-hydroxytryptamine released from vascular adrenergic nerves by periarterial nerve stimulation. J Pharmacol Exp Ther 229: 816-822.
Kawasaki H, Takasaki K, Saito A, and Goto K (1988) Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature (Lond) 335: 164-167.[CrossRef][Medline]
Kawasaki H, Urabe M, and Takasaki K (1987) Enhanced 5-hydroxytryptamine release from vascular adrenergic nerves in spontaneously hypertensive rats. Hypertension 10: 321-327.
Lee TJ, Sarwinski S, Ishine T, Lai CC, and Chen FY (1996) Inhibition of cerebral neurogenic vasodilation by L-glutamine and nitric oxide synthase inhibitors and its reversal by L-citrulline. J Pharmacol Exp Ther 276: 353-358.
Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, Bloom S, and Goldstein M (1982) Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 116: 477-480.[Medline]
Moncada S and Higgs EA (1995) Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 9: 1319-1330.[Abstract]
Oroszi G, Szilvassy Z, Nemeth J, Tosaki A, and Szolcsanyi J (1999) Interplay between nitric oxide and CGRP by capsaicin in isolated guinea-pig heart. Pharmacol Res 40: 125-128.[CrossRef][Medline]
Postorino A, Vetri T, Leggio L, Serio R, and Bonvissuto F (1998) Nitric oxide as neuromodulator of sympathetic transmission in rat vas deferens. J Auton Pharmacol 18: 21-29.[CrossRef][Medline]
Rabelo FA, Russo EM, Salgado MC, and Coelho EB (2001) Nonendothelial NO blunts sympathetic response of normotensive rats but not of SHR. Hypertension 38: 565-568.
Ralevic V (2002) Endothelial nitric oxide modulates perivascular sensory neurotransmission in the rat isolated mesenteric arterial bed. Br J Pharmacol 137: 19-28.[CrossRef][Medline]
Segarra G, Medina P, Revert F, Masia S, Vila JM, Such L, and Aldasoro M (1999) Modulation of adrenergic contraction of dog pulmonary arteries by nitric oxide and prostacyclin. Gen Pharmacol 32: 583-589.[CrossRef][Medline]
Shiraki H, Kawasaki H, Tezuka S, Nakatsuma A, and Kurosaki Y (2000) Endogenous calcitonin gene-related peptide (CGRP) mediates adrenergic-dependent vasodilation induced by nicotine in mesenteric resistance arteries of the rat. Br J Pharmacol 130: 1083-1091.[CrossRef][Medline]
Sosunov AA, Hassall CJ, Loesch A, Turmaine M, and Burnstock G (1995) Ultrastructural investigation of nitric oxide synthase-immunoreactive nerves associated with coronary blood vessels of rat and guinea-pig. Cell Tissue Res 280: 575-582.[Medline]
Takenaga M and Kawasaki H (1999) Endogenous calcitonin gene-related peptide suppresses vasoconstriction mediated by adrenergic nerves in rat mesenteric resistance blood vessels. Eur J Pharmacol 367: 239-245.[CrossRef][Medline]
Toda N and Okamura T (1990) Modification by L-NG-monomethyl arginine (L-NMMA) of the response to nerve stimulation in isolated dog mesenteric and cerebral arteries. Jpn J Pharmacol 52: 170-173.[Medline]
Toda N and Okamura T (1992) Mechanism of neurally induced monkey mesenteric artery relaxation and contraction. Hypertension 19: 161-166.
Yamamoto R, Wada A, Asada Y, Yanagita T, Yuhi T, Niina H, Sumiyoshi A, Kobayashi H, and Lee TJ (1997) Nitric oxide-dependent and -independent norepinephrine release in rat mesenteric arteries. Am J Physiol 272: H207-H210.[Medline]
Zheng ZL, Travagli RA, and Kreulen DL (1999) Patterns of innervation of sympathetic vascular neurons by peptide-containing primary sensory fibers. Brain Res 827: 113-121.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
J. G. R. De Mey, R. Megens, and G. E. Fazzi Functional Antagonism between Endogenous Neuropeptide Y and Calcitonin Gene-Related Peptide in Mesenteric Resistance Arteries J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 930 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stegbauer, Y. Kuczka, O. Vonend, I. Quack, L. Sellin, A. Patzak, A. Steege, K. Langnaese, and L. C. Rump Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R421 - R428. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Stewart, M. S. Medow, C. T. Minson, and I. Taneja Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2161 - H2167. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||